Yukio Tokumitsu

Yukio Tokumitsu

Auto-generated profile, based on publicly available information

Yukio Tokumitsu

Department of Gastroenterological, Breast and Endocrine Surgery, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, Yamaguchi, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
YIYuka Inoue
Yuka Inoue
Shoichi HazamaShoichi Hazama
Shoichi Hazama
NSNobuaki Suzuki
Nobuaki Suzuki
YTYukio Tokumitsu
Yukio Tokumitsu
SKShinsuke Kanekiyo
Shinsuke Kanekiyo
Hiroaki NaganoHiroaki Nagano
Hiroaki Nagano
Cetuximab has activity against colorectal cancers. Recent studies demonstrated that cetuximab induces antibody‐dependent cell‐mediated cytotoxicity via immune cells, and a new immune‐related mechanism of inducing immunogenic cell death. This study aimed to evaluate the immune responses induced by cetuximab in tumor microenvironments at liver metastasis sites of metastatic colorectal cancer patients. We assessed immune cell infiltration in the liver metastatic sites of 53 colorectal cancer patients. These patients were divided into three groups according to the treatment before operation: chemotherapy with cetuximab, chemotherapy without cetuximab, and no chemotherapy. The inflammatory cells in the liver metastatic sites were assessed by hematoxylin–eosin staining, focusing on the invasive margin. The overall inflammatory reaction and number of lymphoid cells were assessed with a four‐point scoring system. We then assessed immune cell infiltration (CD3, CD8 and CD56) in 15 liver metastatic sites. Hematoxylin–eosin staining demonstrated more inflammatory cells in the chemotherapy with cetuximab group than in the other groups (P < 0.001). Of note, inflammatory cells were found in intratumoral areas, and the destruction of cancer cell foci was observed in the chemotherapy with cetuximab group. Moreover, a higher infiltration of CD3+ (P = 0.003), CD8+ (P = 0.003) and CD56+ (P = 0.001) cells was observed in the chemotherapy with cetuximab group than in the other groups. These results suggest that cetuximab might have an immune‐enhancing effect. As such, the immune‐related mechanism of action of cetuximab may enhance the efficacy of combination therapy, such as chemotherapy and immunotherapy using therapeutic peptides.

22 May 2019 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
SMSatoshi Matsukuma
Satoshi Matsukuma
YTYukio Tokumitsu
Yukio Tokumitsu
YSYoshitaro Shindo
Yoshitaro Shindo
HMHiroto Matsui
Hiroto Matsui
Hiroaki NaganoHiroaki Nagano
Hiroaki Nagano
Biliary tract cancer, which includes intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, and ampullary cancer, is an intractable disease with a dismal prognosis. Prognosis is particularly poor in cases involving vessels or lymph nodes. Hepatobiliary pancreatic surgeons worldwide have consistently focused on improving surgical treatment, perioperative management, and chemotherapy to improve the outcomes of these diseases. There has been significant progress even in the last 2 years (2017 and 2018), such as promising findings reported by studies on the optimal extent of surgical treatment and multi‐institutional randomized controlled trials on adjuvant chemotherapy. We overview the current trends and advancements made in surgical treatment in 2017 and 2018.

16 September 2022 in Surgery
Verified
Journal Article
Closed access
SOShinichiro Ono
Shinichiro Ono
TATomohiko Adachi
Tomohiko Adachi
TOTakao Ohtsuka
Takao Ohtsuka
RKRyuichiro Kimura
Ryuichiro Kimura
KNKazuyoshi Nishihara
Kazuyoshi Nishihara
Susumu EguchiSusumu Eguchi
Susumu Eguchi

19 January 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YTYukio Tokumitsu
Yukio Tokumitsu
KSKazuhiko Sakamoto
Kazuhiko Sakamoto
YTYoshihiro Tokuhisa
Yoshihiro Tokuhisa
HMHiroto Matsui
Hiroto Matsui
SMSatoshi Matsukuma
Satoshi Matsukuma
HNHiroaki Nagano
Hiroaki Nagano
We previously reported the effectiveness of the product of tumor number and size (NxS factor) for the prognosis of hepatocellular carcinoma (HCC) in patients following hepatectomy. The present study aimed to propose a new score based on the NxS factor to predict HCC recurrence following hepatectomy. A total of 406 patients who underwent hepatectomy for HCC at Osaka University Graduate School of Medicine were retrospectively analyzed to develop the new score. Among clinicopathological factors, including the NxS factor, the marker subset that achieved the best performance for prediction of early recurrence was assessed, and a prognostic model for HCC recurrence after curative hepatectomy (REACH) was developed. As the validation set, 425 patients who underwent hepatectomy for HCC at Yamaguchi University Graduate School of Medicine and Shimonoseki Medical Center were analyzed, and the prognostic ability of the REACH score was compared with that of well‑known staging systems. Following analysis, the REACH score was constructed using six covariates (NxS factor, microscopic hepatic vein invasion, differentiation, serum albumin, platelet count and indocyanine green retention rate at 15 min). In the validation set, the REACH score predicted early recurrence in 73 of 81 samples, with a sensitivity of 89% and a specificity of 58%. The area under the curve (AUC) of the receiver operating characteristic curve of the REACH score was 0.78 and 0.74, respectively, for 1‑ and 2‑year recurrence after hepatectomy; each AUC was higher than that of any of the other staging systems. Survival analysis indicated the REACH score had the best predictive value in disease‑free and overall survival. The present findings demonstrated that the REACH score may be used to classify patients with HCC into high‑ and low‑risk of recurrence, and to predict subsequent survival following hepatic resection.

17 September 2020 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
STShigeru Takeda
Shigeru Takeda
MIMichihisa Iida
Michihisa Iida
SKShinsuke Kanekiyo
Shinsuke Kanekiyo
MNMitsuo Nishiyama
Mitsuo Nishiyama
YTYukio Tokumitsu
Yukio Tokumitsu
Hiroaki NaganoHiroaki Nagano
Hiroaki Nagano
Aim: To evaluate the efficacy of intraoperative neuromonitoring in identifying recurrent laryngeal nerves and decreasing the incidence of nerve injury in minimally invasive esophagectomies for esophageal cancers.Methods: A total of 167 minimally invasive esophagectomy patients were retrospectively reviewed. They were divided into intraoperative neuromonitoring (n = 84) and no intraoperative neuromonitoring (n = 83) groups, based on whether or not intraoperative neuromonitoring was used during surgery. We compared short‐term surgical outcomes and incidence of recurrent laryngeal nerve palsy between the two groups before and after propensity score matching. The association between the loss of signal and recurrent laryngeal nerve palsy was also evaluated.Results: The incidence of recurrent laryngeal nerve palsy (grade 2 and higher) was lower in the intraoperative neuromonitoring group than in the no intraoperative neuromonitoring group (6.0% vs 21.2%, P = 0.02). The rate of recurrent laryngeal nerve palsy recovery within 6 months was also significantly higher in the intraoperative neuromonitoring group (87.5% vs 20.0%, P < 0.01). The positive and negative predictive values of intraoperative neuromonitoring for recurrent laryngeal nerve palsy were 60% (9/15) and 86.9% (60/69), respectively. The duration from paralysis to recovery was shorter in recurrent laryngeal nerve palsy cases with negative loss of signal results than in cases with positive loss of signal results (median: 43 days vs 95 days).Conclusion: Intraoperative neuromonitoring is useful in identifying recurrent laryngeal nerves and may aid in reducing the incidence of recurrent laryngeal nerve injury during esophageal surgery.

11 November 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TFTakuya Fujimoto
Takuya Fujimoto
RTRyouichi TSUNEDOMI
Ryouichi TSUNEDOMI
SMSatoshi Matsukuma
Satoshi Matsukuma
KYKiyoshi Yoshimura
Kiyoshi Yoshimura
AOAtsunori Oga
Atsunori Oga
Hiroaki NaganoHiroaki Nagano
Hiroaki Nagano
Cancer stem‑like cells (CSLCs) in solid tumors are resistant to conventional chemotherapy and molecularly targeted therapy, which is thought to contribute to cancer recurrence and metastasis. The present study aimed to identify biomarkers for pancreatic CSLCs (P‑CSLCs). Using our previously reported methods, P‑CSLC‑enriched populations were generated from pancreatic cancer cell lines. The protein expression profiles of these populations were compared with those of parental cells using two‑dimensional electrophoresis, tandem mass spectrometry, flow cytometry and immunohistochemistry. Protein expression in surgical specimens was also evaluated for relationships with clinical outcomes. A lysosomal cysteine protease, cathepsin B (CTSB), was significantly upregulated in P‑CSLCs compared with that in the parental cells, as shown using western blotting. Flow cytometry analysis also confirmed that CTSB was more highly expressed on the surface of P‑CSLCs compared with that on parental cells. Moreover, PCLCs had elevated cellular secretions of CTSB compared with the parental cells. Finally, CTSB expression was evaluated in 69 resected tumor specimens, and high expression was associated with the patients' clinicopathological features and surgical outcomes. The present results suggested that CTSB is a biomarker for poor survival in patients with pancreatic cancer, which is possibly associated with P‑CSLCs. This novel biomarker may also have potential as a therapeutic target.